Literature DB >> 24478482

Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Luke C Swenson1, Bryan Cobb, Anna Maria Geretti, P Richard Harrigan, Mario Poljak, Carole Seguin-Devaux, Chris Verhofstede, Marc Wirden, Alessandra Amendola, Jurg Boni, Thomas Bourlet, Jon B Huder, Jean-Claude Karasi, Snjezana Zidovec Lepej, Maja M Lunar, Odette Mukabayire, Rob Schuurman, Janez Tomazic, Kristel Van Laethem, Linos Vandekerckhove, Annemarie M J Wensing.   

Abstract

Low-level viremia during antiretroviral therapy and its accurate measurement are increasingly relevant. Here, we present an international collaboration of 4,221 paired blood plasma viral load (pVL) results from four commercial assays, emphasizing the data with low pVL. The assays compared were the Abbott RealTime assay, the Roche Amplicor assay, and the Roche TaqMan version 1 and version 2 assays. The correlation between the assays was 0.90 to 0.97. However, at a low pVL, the correlation fell to 0.45 to 0.85. The observed interassay concordance was higher when detectability was defined as 200 copies/ml than when it was defined as 50 copies/ml. A pVL of ∼100 to 125 copies/ml by the TaqMan version 1 and version 2 assays corresponded best to a 50-copies/ml threshold with the Amplicor assay. Correlation and concordance between the viral load assays were lower at a low pVL. Clear guidelines are needed on the clinical significance of low-level viremia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24478482      PMCID: PMC3911321          DOI: 10.1128/JCM.02461-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  40 in total

1.  HIV-1 load comparison using four commercial real-time assays.

Authors:  Thomas Bourlet; Anne Signori-Schmuck; Laurent Roche; Vinca Icard; Henia Saoudin; Mary-Anne Trabaud; Jean-Claude Tardy; Patrice Morand; Bruno Pozzetto; René Ecochard; Patrice André
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

2.  Upgraded Cobas Ampliprep-Cobas TaqMan version 2.0 HIV-1 RNA quantification assay versus first version: correction of underestimations.

Authors:  M Wirden; R Tubiana; S Fourati; M Thevenin; A Simon; A Canestri; Z Ait-Arkoub; C Soulie; A G Marcelin; C Katlama; V Calvez
Journal:  J Clin Microbiol       Date:  2011-05-04       Impact factor: 5.948

3.  High correlation between the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes.

Authors:  J C Karasi; F Dziezuk; L Quennery; S Förster; U Reischl; G Colucci; D Schoener; C Seguin-Devaux; J C Schmit
Journal:  J Clin Virol       Date:  2011-08-03       Impact factor: 3.168

4.  Performance evaluation of the COBAS/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study.

Authors:  Pierpaolo Paba; Lavinia Fabeni; Massimo Ciccozzi; Carlo Federico Perno; Marco Ciotti
Journal:  J Virol Methods       Date:  2011-03-16       Impact factor: 2.014

5.  Standardization and performance evaluation of "modified" and "ultrasensitive" versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia.

Authors:  Alessandra Amendola; Maria Bloisi; Patrizia Marsella; Rosella Sabatini; Angela Bibbò; Claudio Angeletti; Maria Rosaria Capobianchi
Journal:  J Clin Virol       Date:  2011-07-20       Impact factor: 3.168

6.  Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test.

Authors:  James H Willig; Christa R Nevin; James L Raper; Michael S Saag; Michael J Mugavero; Amanda L Willig; Jeffrey H Burkhardt; Joseph E Schumacher; Victoria A Johnson
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

7.  Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.

Authors:  Steven A Yukl; Peilin Li; Katsuya Fujimoto; Harry Lampiris; Chuanyi M Lu; C Bradley Hare; Steven G Deeks; Teri Liegler; Mark Pandori; Diane V Havlir; Joseph K Wong
Journal:  J Virol Methods       Date:  2011-04-22       Impact factor: 2.014

8.  Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification.

Authors:  Celine S Yan; Imelda Hanafi; Anthony D Kelleher; Andrew D Carr; Janaki Amin; Leon P McNally; Philip H Cunningham
Journal:  J Clin Virol       Date:  2010-09-29       Impact factor: 3.168

9.  Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance.

Authors:  J W Cohen Stuart; A M Wensing; C Kovacs; M Righart; D de Jong; S Kaye; R Schuurman; C J Visser; C A Boucher
Journal:  J Acquir Immune Defic Syndr       Date:  2001-10-01       Impact factor: 3.731

10.  Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.

Authors:  Ninon Taylor; Katharina Grabmeier-Pfistershammer; Alexander Egle; Richard Greil; Armin Rieger; Bruno Ledergerber; Hannes Oberkofler
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

View more
  19 in total

1.  Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity.

Authors:  Christina M Lalama; Cheryl Jennings; Victoria A Johnson; Robert W Coombs; John E McKinnon; James W Bremer; Bryan R Cobb; Gavin A Cloherty; John W Mellors; Heather J Ribaudo
Journal:  J Clin Microbiol       Date:  2015-06-10       Impact factor: 5.948

2.  Point-of-Care Cepheid Xpert HIV-1 Viral Load Test in Rural African Communities Is Feasible and Reliable.

Authors:  Sikhulile Moyo; Terence Mohammed; Kathleen E Wirth; Melanie Prague; Kara Bennett; Molly Pretorius Holme; Lucy Mupfumi; Philemon Sebogodi; Natasha O Moraka; Corretah Boleo; Comfort N Maphorisa; Boitumelo Seraise; Simani Gaseitsiwe; Rosemary M Musonda; Erik van Widenfelt; Kathleen M Powis; Tendani Gaolathe; Eric J Tchetgen Tchetgen; Joseph M Makhema; Max Essex; Shahin Lockman; Vladimir Novitsky
Journal:  J Clin Microbiol       Date:  2016-10-12       Impact factor: 5.948

3.  Human immunodeficiency virus infection induces lymphoid fibrosis in the BM-liver-thymus-spleen humanized mouse model.

Authors:  Jasmine Samal; Samantha Kelly; Ali Na-Shatal; Abdallah Elhakiem; Antu Das; Ming Ding; Anwesha Sanyal; Phalguni Gupta; Kevin Melody; Brad Roland; Watfa Ahmed; Aala Zakir; Moses Bility
Journal:  JCI Insight       Date:  2018-09-20

4.  Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load.

Authors:  Orna Mor; Yael Gozlan; Marina Wax; Fernando Mileguir; Avia Rakovsky; Bina Noy; Ella Mendelson; Itzchak Levy
Journal:  J Clin Microbiol       Date:  2015-08-19       Impact factor: 5.948

5.  Improved HIV-1 Viral Load Monitoring Capacity Using Pooled Testing With Marker-Assisted Deconvolution.

Authors:  Tao Liu; Joseph W Hogan; Michael J Daniels; Mia Coetzer; Yizhen Xu; Gerald Bove; Allison K DeLong; Lauren Ledingham; Millicent Orido; Lameck Diero; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

6.  Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays.

Authors:  Alessandra Amendola; Patrizia Marsella; Maria Bloisi; Federica Forbici; Claudio Angeletti; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

7.  Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials.

Authors:  Will Garner; Kirsten White; Javier Szwarcberg; Scott McCallister; Lijie Zhong; Mike Wulfsohn
Journal:  Clin Infect Dis       Date:  2015-12-21       Impact factor: 9.079

8.  All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study.

Authors:  Olof Elvstam; Gaetano Marrone; Patrik Medstrand; Carl Johan Treutiger; Anders Sönnerborg; Magnus Gisslén; Per Björkman
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

9.  Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study.

Authors:  Jim Young; Martin Rickenbach; Alexandra Calmy; Enos Bernasconi; Cornelia Staehelin; Patrick Schmid; Matthias Cavassini; Manuel Battegay; Huldrych F Günthard; Heiner C Bucher
Journal:  BMC Infect Dis       Date:  2015-09-21       Impact factor: 3.090

10.  Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.

Authors:  Laura Marije Hofstra; Tania Mudrikova; Arjen J Stam; Sigrid Otto; Kiki Tesselaar; Monique Nijhuis; Annemarie M J Wensing
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.